<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341431</url>
  </required_header>
  <id_info>
    <org_study_id>P090102</org_study_id>
    <nct_id>NCT01341431</nct_id>
  </id_info>
  <brief_title>Bee Venom for the Treatment of Parkinson Disease</brief_title>
  <acronym>MIREILLE</acronym>
  <official_title>Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of repeated (monthly) injections of bee
      venom on motor symptoms of Parkinson's disease over a period of one year, also the potential
      effects of this treatment on disease progression compared to placebo (saline injections).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to assess the potential efficacy of repeated (monthly) injections of
      bee venom on the motor symptoms of Parkinson disease over a period of one year. The
      investigators will also assess the potential effects of this treatment on disease
      progression. All assessments will be conducted in comparison to placebo (saline injections).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UPDRS III scores</measure>
    <time_frame>one year</time_frame>
    <description>Quantify the magnitude of a potential long-term symptomatic effect of bee venom by comparing UPDRS III scores at study inclusion and the final visit one year later before and after bee venom injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the potential effect of bee venom on disease progression by comparing UPDRS III off scores between treated/placebo group</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in L-Dopa equivalence doses over 12 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate symptom (UPDRS III) progression with nigrostriatal denervation as measured by DaTSCAN</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify the evolution (appearance, progression or regression) of motor fluctuations over the one year study period by UPDRS IV</measure>
    <time_frame>&gt; 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>bee venom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bee venom</intervention_name>
    <description>12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.</description>
    <arm_group_label>bee venom</arm_group_label>
    <arm_group_label>saline</arm_group_label>
    <other_name>1: Experimental : Bee venom</other_name>
    <other_name>2: Placebo Comparator : NaCl 0.9%, 1 milliliter s.c.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from Parkinson disease according to the Parkinson's Disease Society
             Brain Bank criteria (Hughes et al., 1992)

          -  Age &gt; 40 ans (exclusion of juvenile forms)

          -  Hoehn and Yahr stage 1,5-3 off

          -  Pathological DaTSCAN

          -  MRI excluding atypical or secondary forms of parkinsonism

          -  Negative testing to bee venom (intradermoreaction)

          -  Affiliated to the French Social Security System

        Exclusion Criteria:

          -  Parkinson disease Hoehn &amp; Yahr stage &lt; 1,5 or &gt; 3

          -  Positive intradermoreaction to bee venom

          -  IgE positive to bee venom

          -  Known allergy to bee venom

          -  Contra-indications to treatment with bee venom (Alyostal®)

          -  Atypical or secondary parkinsonian syndrome (verified by MRI)

          -  Treatment with antipsychotics over the past 6 months

          -  Cardiac, hepatic or renal failure

          -  Normal DaTSCAN

          -  Contra-indications to MRI scanning

          -  Pregnancy

          -  Major depression or other severe acute/ongoing psychiatric disorder

          -  Cognitive impairment (MMS &gt;24)

          -  Patient under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hartmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique ICM</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>June 13, 2014</last_update_submitted>
  <last_update_submitted_qc>June 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>Bee venom</keyword>
  <keyword>Motor fluctuations</keyword>
  <keyword>Disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

